About Hereditary Antithrombin Deficiency

Hereditary antithrombin deficiency presents the highest risk of thrombosis among inherited thrombophilias.

Increased Thrombotic Risk1

Graph: Inherited risk

Adapted from Franchini et al.1

Thrombate III is not indicated for the treatment of thrombophilias other than hereditary antithrombin deficiency.

Statistics of Patients with Hereditary AT Deficiency

  • Greater than 85% of those who are >50 years old have had at least one prior thrombotic episode, and of these patients, thrombosis is recurrent in about 60%2
  • Hereditary AT deficiency may account for as many as 3% of all patients diagnosed with venous thromboembolism1
  • Incidence of thromboembolism among pregnant women with hereditary AT deficiency may be as high as 70%3

References:

  1. Franchini M, Veneri JD, Salvagno GL, Manzato F, Lippi G. Inherited thrombophilia. Crit Rev Clin Lab Sci. 2006;4393:249-290.
  2. Thaler E, Lechner K. Antithrombin III deficiency and thromboembolism. Clin Haematol. 1981;10(2):369-390.
  3. Hellgren M, Tengborn L, Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest. 1982;14(2):127-141.

Important Safety Information

Thrombate III is indicated for the treatment of patients with hereditary antithrombin deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.

In clinical studies with Thrombate III, the most common side effects were dizziness, chest tightness, nausea, and foul taste in the mouth.

The anticoagulant effect of heparin is enhanced by concurrent treatment with Thrombate III in patients with hereditary AT-III deficiency. Thus, in order to avoid bleeding, reduced dosage of heparin is recommended during treatment with Thrombate III.

Thrombate III is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent that can cause disease. There is also the possibility that unknown infectious agents may be present in such products.

Individuals who receive infusions of blood or blood plasma may develop signs and/or symptoms of some viral infections, particularly hepatitis C.

Please speak to your doctor and refer to Thrombate III Prescribing Information for full details.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.